Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

NCT04916509 · clinicaltrials.gov ↗

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Palbociclib plus an aromatase inhibitor
DRUG: Palbociclib plus fulvestrant

Sponsor

Pfizer